Literature DB >> 30429350

Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.

James D Allen1, Hyesun Jang1, Joshua DiNapoli2, Harold Kleanthous2, Ted M Ross3,4.   

Abstract

The vast majority of people already have preexisting immune responses to influenza viruses from one or more subtypes. However, almost all preclinical studies evaluate new influenza vaccine candidates in immunologically naive animals. Recently, our group demonstrated that priming naive ferrets with broadly reactive H1 COBRA HA-based vaccines boosted preexisting antibodies induced by wild-type H1N1 virus infections. These H1 COBRA hemagglutinin (HA) antigens induced antibodies with HAI activity against multiple antigenically different H1N1 viral variants. In this study, ferrets, preimmune to historical H3N2 viruses, were vaccinated with virus-like particle (VLP) vaccines expressing either an HA from a wild-type H3 influenza virus or a COBRA H3 HA antigen (T6, T7, T10, or T11). The elicited antisera had the ability to neutralize virus infection against either a panel of viruses representing vaccine strains selected by the World Health Organization or a set of viral variants that cocirculated during the same time period. Preimmune animals vaccinated with H3 COBRA T10 HA antigen elicited sera with higher hemagglutination inhibition (HAI) antibody titers than antisera elicited by VLP vaccines with wild-type HA VLPs in preimmune ferrets. However, while the T11 COBRA vaccine did not elicit HAI activity, the elicited antibodies did neutralize antigenically distinct H3N2 influenza viruses. Overall, H3 COBRA-based HA vaccines were able to neutralize both historical H3 and contemporary, as well as future, H3N2 viruses with higher titers than vaccines with wild-type H3 HA antigens. This is the first report demonstrating the effectiveness of a broadly reactive H3N3 vaccine in a preimmune ferret model.IMPORTANCE After exposure to influenza virus, the host generates neutralizing anti-hemagglutinin (anti-HA) antibodies against that specific infecting influenza strain. These antibodies can also neutralize some, but not all, cocirculating strains. The goal of next-generation influenza vaccines, such as HA head-based COBRA, is to stimulate broadly protective neutralizing antibodies against all strains circulating within a subtype, in particular those that persist over multiple influenza seasons, without requiring an update to the vaccine. To mimic the human condition, COBRA HA virus-like particle vaccines were tested in ferrets that were previously exposed to historical H3N2 influenza viruses. In this model, these vaccines elicited broadly protective antibodies that neutralized cocirculating H3N2 influenza viruses isolated over a 20-year period. This is the first study to show the effectiveness of H3N3 COBRA HA vaccines in a host with preexisting immunity to influenza.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  COBRA; H3N2; broadly protective vaccine; ferrets; hemagglutination inhibition; influenza; neutralization

Mesh:

Substances:

Year:  2019        PMID: 30429350      PMCID: PMC6340030          DOI: 10.1128/JVI.00946-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Epitope analysis for influenza vaccine design.

Authors:  Enrique T Muñoz; Michael W Deem
Journal:  Vaccine       Date:  2005-01-19       Impact factor: 3.641

2.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 3.  Animal models for evaluation of influenza vaccines.

Authors:  Ralph A Tripp; S Mark Tompkins
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

Review 4.  Structural basis of immune recognition of influenza virus hemagglutinin.

Authors:  I A Wilson; N J Cox
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

5.  Predicting Influenza H3N2 Vaccine Efficacy From Evolution of the Dominant Epitope.

Authors:  Melia E Bonomo; Michael W Deem
Journal:  Clin Infect Dis       Date:  2018-09-14       Impact factor: 9.079

6.  Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.

Authors:  Brendan M Giles; Stephanie J Bissel; Dilhari R Dealmeida; Clayton A Wiley; Ted M Ross
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

7.  Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.

Authors:  Rory D de Vries; Nella J Nieuwkoop; Mark Pronk; Erwin de Bruin; Geert Leroux-Roels; Elisabeth G W Huijskens; Rob S van Binnendijk; Florian Krammer; Marion P G Koopmans; Guus F Rimmelzwaan
Journal:  Vaccine       Date:  2016-11-30       Impact factor: 3.641

8.  Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses.

Authors:  H H Walls; M W Harmon; J J Slagle; C Stocksdale; A P Kendal
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

9.  Changing selective pressure during antigenic changes in human influenza H3.

Authors:  Benjamin P Blackburne; Alan J Hay; Richard A Goldstein
Journal:  PLoS Pathog       Date:  2008-05-02       Impact factor: 6.823

10.  Influenza evolution and H3N2 vaccine effectiveness, with application to the 2014/2015 season.

Authors:  Xi Li; Michael W Deem
Journal:  Protein Eng Des Sel       Date:  2016-06-16       Impact factor: 1.650

View more
  15 in total

1.  An Influenza Virus Hemagglutinin Computationally Optimized Broadly Reactive Antigen Elicits Antibodies Endowed with Group 1 Heterosubtypic Breadth against Swine Influenza Viruses.

Authors:  Amanda L Skarlupka; Z Beau Reneer; Rodrigo B Abreu; Ted M Ross; Giuseppe A Sautto
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

2.  Differential Recognition of Computationally Optimized H3 Hemagglutinin Influenza Vaccine Candidates by Human Antibodies.

Authors:  Nada Abbadi; Kaito Nagashima; Alma Pena-Briseno; Ted M Ross; Jarrod J Mousa
Journal:  J Virol       Date:  2022-08-02       Impact factor: 6.549

3.  Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Authors:  James D Allen; Ted M Ross
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

4.  Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges.

Authors:  Z Beau Reneer; Parker J Jamieson; Amanda L Skarlupka; Ying Huang; Ted M Ross
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

5.  Computationally optimized broadly reactive vaccine based upon swine H1N1 influenza hemagglutinin sequences protects against both swine and human isolated viruses.

Authors:  Amanda L Skarlupka; Simon O Owino; Lui P Suzuki-Williams; Corey J Crevar; Donald M Carter; Ted M Ross
Journal:  Hum Vaccin Immunother       Date:  2019       Impact factor: 3.452

Review 6.  Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.

Authors:  Jesús Zepeda-Cervantes; Josué Orlando Ramírez-Jarquín; Luis Vaca
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

7.  Efficacy of Heterologous Prime-Boost Vaccination with H3N2 Influenza Viruses in Pre-Immune Individuals: Studies in the Pig Model.

Authors:  Sharon Chepkwony; Anna Parys; Elien Vandoorn; Koen Chiers; Kristien Van Reeth
Journal:  Viruses       Date:  2020-09-01       Impact factor: 5.048

8.  Pre-existing heterosubtypic immunity provides a barrier to airborne transmission of influenza viruses.

Authors:  Valerie Le Sage; Jennifer E Jones; Karen A Kormuth; William J Fitzsimmons; Eric Nturibi; Gabriella H Padovani; Claudia P Arevalo; Andrea J French; Annika J Avery; Richard Manivanh; Elizabeth E McGrady; Amar R Bhagwat; Adam S Lauring; Scott E Hensley; Seema S Lakdawala
Journal:  PLoS Pathog       Date:  2021-02-18       Impact factor: 6.823

9.  N-Glycolylneuraminic Acid in Animal Models for Human Influenza A Virus.

Authors:  Cindy M Spruit; Nikoloz Nemanichvili; Masatoshi Okamatsu; Hiromu Takematsu; Geert-Jan Boons; Robert P de Vries
Journal:  Viruses       Date:  2021-05-01       Impact factor: 5.048

10.  Influenza imprinting in childhood and the influence on vaccine response later in life.

Authors:  Alyson A Kelvin; Maria Zambon
Journal:  Euro Surveill       Date:  2019-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.